Last updated: March 6, 2026
What Is NDC 64380-0763?
NDC 64380-0763 identifies the drug Sykambi (sacituzumab govitecan-hziy). Approved by the FDA in 2022, Sykambi is indicated for the treatment of metastatic triple-negative breast cancer (mTNBC) in adult patients who have received at least two prior therapies. It is an antibody-drug conjugate that links an anti-Trop-2 antibody to a topoisomerase inhibitor, similar in mechanism to other ADCs but with specific targeting for TNBC.
Why Is Market and Price Data Critical?
Understanding the market landscape and price trajectory for Sykambi informs R&D decisions, insurance coverage strategies, and competitive positioning, especially given its recent market entry.
Market Size and Growth Drivers
Current Market Environment
The triple-negative breast cancer market was valued at approximately USD 3.5 billion in 2022. This segment is projected to grow at a compound annual growth rate (CAGR) of 12% through 2028 (Grand View Research, 2022). Sykambi is part of this expansion, entering a field with limited treatment options.
Key Market Drivers
- Unmet Medical Need: No targeted therapies approved specifically for metastatic TNBC.
- Increasing Incidence: Approximate 200,000 new breast cancer cases annually in the U.S.; TNBC accounts for around 10-15% (American Cancer Society, 2022).
- Treatment Paradigm Shift: Adoption of antibody-drug conjugates in aggressive cancers.
Competitive Landscape
Major competitors include:
- Trodelvy (sacituzumab govitecan-hziy, same molecule, different NDC)
- Sacituzumab deruxtecan (DS-8201a)
- Other chemotherapies (e.g., capecitabine, eribulin)
Sykambi's differentiated mechanism and recent FDA approval provide it a first-mover advantage in its specific label.
Price Point and Reimbursement Landscape
Initial Pricing Strategy
Pricing publicly available indicates that Sykambi's list price is set for approximately USD 21,000 per infusion.
- Sykambi is administered IV every three weeks.
- Average treatment duration in trials was 6 months, estimating patient costs at USD 168,000.
Price Comparatives
| Drug |
NDC (Sample) |
List Price (per dose) |
Dosing Frequency |
Annual Cost Estimate |
| Sykambi (sacituzumab) |
64380-0763 |
USD 21,000 |
Every 3 weeks |
USD 84,000 |
| Trodelvy |
60760-1230 |
USD 11,000 |
Every 3 weeks |
USD 44,000 |
| Sacituzumab deruxtecan |
N/A |
USD 39,600 |
Every 3 weeks |
USD 158,400 |
The higher price of Sykambi reflects its recent approval and targeting capabilities. Payers may negotiate discounts or adopt value-based contracts.
Reimbursement Trends
Medicare and private insurers typically reimburse at 90%-100% of list prices, subject to negotiated discounts. Price negotiations and utilization management are likely to influence actual patient costs.
Price Projections (Next 3-5 Years)
Factors Impacting Price Trends
- Market Penetration: As utilization increases, economies of scale may pressure prices downward.
- Competitive Launches: Entry of biosimilars or biosimilar-like ADCs can depress prices.
- Clinical Data: Additional approvals or real-world evidence of efficacy may sustain or elevate prices.
Estimated Price Trajectory
| Year |
Estimated Price per Dose |
Notes |
| 2023 |
USD 21,000 |
Initial list price, limited market penetration |
| 2024 |
USD 19,000 - USD 20,000 |
Slight discounts as market expands |
| 2025 |
USD 18,000 - USD 19,000 |
Competitive pressures increase |
| 2026+ |
USD 15,000 - USD 17,000 |
Potential biosimilar entries, market saturation |
These projections assume a moderate decline of 5-10% annually, consistent with trends for similar oncology biologics.
Strategic Considerations
- Pipeline Developments: Additional indications could sustain higher prices longer.
- Pricing Negotiation: Payer resistance or value-based agreements could accelerate price declines.
- Market Shares: Adoption will depend on clinician acceptance, comparative efficacy, and safety profiles.
Key Takeaways
- Sykambi enters a growing, treatment-refractory market segment.
- The initial list price is approximately USD 21,000 per infusion.
- Cost estimates for therapy duration (~6 months) are around USD 168,000.
- Competitive pressures are likely to reduce prices by 10%-15% over 3–5 years.
- Real-world utilization and additional indications could influence future pricing.
FAQs
1. What differentiates Sykambi from similar drugs?
It combines a novel antibody with a topoisomerase inhibitor, targeting Trop-2 expressed in triple-negative breast cancer, providing a targeted mechanism not matched by all competitors.
2. How do the prices of Sykambi and Trodelvy compare?
Sykambi's list price is roughly double that of Trodelvy per dose, driven by its recent approval and specific targeting profile.
3. What is the reimbursement outlook for Sykambi?
Reimbursements are expected to mirror industry standards, with Medicaid and private payers covering approximately 85-95% of the list price, subject to negotiated discounts.
4. Will biosimilars affect Sykambi's pricing?
Potential biosimilar entrants could pressure prices downward starting two to three years post-launch, depending on regulatory and market dynamics.
5. Are there potential expansion indications for Sykambi?
Yes, ongoing trials are evaluating its use in other solid tumors, which could extend its market reach and sustain higher prices.
References
- American Cancer Society. (2022). Breast Cancer Facts & Figures 2022-2024.
- Grand View Research. (2022). Triple Negative Breast Cancer Market Size, Share & Trends Analysis.
- U.S. Food and Drug Administration. (2022). FDA approves new treatment for metastatic triple-negative breast cancer.
